⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056084 | 0.85 | — | — | |
| SCHEMBL8363424 | 0.75 | NOS3 (0.34) | — | |
| SCHEMBL8468982 | 0.71 | — | — | |
| SCHEMBL8775933 | 0.54 | — | — | |
| SCHEMBL3221127 | 0.54 | TSHR (0.37) | — | |
| SCHEMBL10545264 | 0.39 | — | — | |
| SCHEMBL300801 | 0.39 | IDO1 (0.31) | — | |
| SCHEMBL2326 | 0.37 | — | — | |
| SCHEMBL34570 | 0.37 | — | — | |
| SCHEMBL25407819 | 0.34 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250302827-A1 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | UNIV EMORY (US) | 2025-10-02 | — | — | US | disclosed |
| US-12357629-B2 | Uses of BCL-2 antagonists for treating cancer and diagnostics related thereto | EMORY UNIVERSITY (US) | 2025-07-15 | — | — | US | disclosed |
| CN-115991678-B | Diketopiperazine compound, preparation method and application thereof | 上海惠永药物研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-113527217-B | Diketopiperazine compound and application thereof | 上海惠永药物研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-113527216-B | Preparation method of diketopiperazine compound, intermediate thereof and preparation method thereof | 上海惠永药物研究有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2006122250-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060148867-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065646-A1 | BENZISOTHIAZOLE-1, 1-DIOXIDE ACTING AS ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006062981-A2 | ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | disclosed |
| CN-1686976-A | Conjugated ramification material of fluorine containing anthracene and pyrene at 9th position, preparation method and application | UNIV FUDAN (CN) | 2005-10-26 | — | — | CN | disclosed |